Basiliximab Injectable Solution

Basiliximab Injectable Solution

Form: Injectable Solution

Strength: 20 mg/vial

Reference Brands: Simulect(US)

Category: Transplant

Basiliximab injection, marketed as Simulect, is approved in the US by the FDA and in the EU via EMA for preventing organ rejection in kidney transplantation. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews extensive clinical trial and quality data, while the EMA ensures compliance with safety and manufacturing regulations. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports timely approval, safe use, and broad availability, helping transplant patients achieve graft survival and improve long-term outcomes worldwide.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Cotrimoxazole tablets

Strength: 80 mg trimethoprim / 400 mg sulfamethoxazole

Form: Tablets

Reference Brands: Bactrim, Septra(US & EU)

View Details Get Enquiry
Acyclovir tablet

Strength: 200 mg, 400 mg, 800 mg

Form: Tablets

Reference Brands: Zovirax(US & EU)

View Details Get Enquiry
Belatacept injection

Strength: 250 mg/vial

Form: Injection

Reference Brands: Nulojix(US)

View Details Get Enquiry
Prednisolone syrup

Strength: 15 mg/5ml

Form: Syrup

Reference Brands: Orapred(US)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.